Supreme Court denies POM’s request to review ruling that ads were deceptive

May 2, 2016

Marketers have been watching the FTC’s challenge to POM Wonderful’s ad claims with interest. Last year, the United States Court of Appeals for the D.C. Circuit ruled that the company deceptively advertised that the products could treat, prevent, or reduce the risk of heart disease, prostate cancer, and erectile dysfunction. The D.C. Circuit also upheld the Commission’s finding that POM falsely claimed to have clinical proof to support those representations. The latest word on the subject: The Supreme Court just denied the company’s request to review the decision. If it’s been a while since you’ve read the ruling, is it time to take another look at what the D.C. Circuit said about substantiating health claims?

Add new comment

Comment Policy

Privacy Act Statement

It is your choice whether to submit a comment. If you do, you must create a user name, or we will not post your comment. The Federal Trade Commission Act authorizes this information collection for purposes of managing online comments. Comments and user names are part of the Federal Trade Commission’s (FTC) public records system (PDF), and user names also are part of the FTC’s computer user records system (PDF). We may routinely use these records as described in the FTC’s Privacy Act system notices. For more information on how the FTC handles information that we collect, please read our privacy policy.